Abstract: A method for forming an organic material layer on a substrate in an in-line deposition system is disclosed. In one aspect, the organic material is deposited with a predetermined non-constant deposition rate profile, which includes a first predetermined deposition rate range provided to deposit at least a first monolayer of the organic material layer with a first predetermined average deposition rate and a second predetermined deposition rate range provided to deposit at least a second monolayer of the organic material layer with a second predetermined average deposition rate. The injection of organic material through the openings of the injector is controlled for realizing the predetermined deposition rate profile.

Abstract: Biomaterial having a multi-dimensional structure and comprising differentiated MSCs tissue and demineralised bone matrix, wherein said demineralised bone matrix is dispersed within the differentiated MSCs tissue, method for producing the same and use thereof.

Abstract: The invention relates to a polyelectrolyte-based nanostructured anticorrosion coating, comprising at least one main compartment which comprises: a polyelectrolyte multilayer (1) doped with at least one anticorrosion agent (4), and an upper multilayer (2a) acting as a barrier to the diffusion of the dopants, and whose upper surface corresponds to the upper surface of the main compartment, and optionally one or more secondary compartments, each comprising: a polyelectrolyte multilayer (8; 11) doped with at least one functional agent other than an anticorrosion agent, and an upper multilayer (2b; 2c) acting as a barrier to the diffusion of the dopants, and whose upper surface corresponds to the upper surface of the secondary compartment. The invention also relates to a structure comprising a metallic substrate and such a coating, and also to its use in the aeronautical or aerospace field and to the process for preparing it.

Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.

Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.

Abstract: The present invention provides a method for capacitive detection of the presence of target sample on a substrate, which comprises the steps of: binding a target sample to selective binding sites on the substrate, the target sample being directly or indirectly labeled with conductive labels, and sensing the presence of the bound conductive labels to a binding site to thereby determine the presence of the target sample. The sensing step is carried out by a capacitive detection of the presence of the conductive labels. The present invention also provides a capacitive sensor device for determining the presence of a target sample. Conductive labels are directly or indirectly couplable to the target sample.

Abstract: Compounds having the general formula II, III, or IV wherein R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y can be either CH, CH2, O, S, OCH2, N—R, N—Ar, C—R, C—Ar; Z can be either H, O, S, S—R or NR.

Abstract: The present invention is directed to a method for filtering a liquid, such as beer, comprising carrying out the filtration of said liquid in the presence of a filter aid, wherein said filter aid essentially comprises porous or non porous polyolefin particles having a specific mass less than 1000 kg/m3 and having an at least partly oxidized outer surface, whereby said outer surface is provided with nodular structures.

Abstract: Methods for the determination and the classification of a rheumatic condition in a synovial sample of a subject afflicted with a rheumatic condition are disclosed. Methods include the steps of determining in the level of expression of at least 20 genes or gene fragments in the synovial sample and identifying whether the level of expression of the genes in the sample correlates with the presence of a rheumatic condition. Kits are also described for the determination and the classification of rheumatic conditions which contain a low density microarray having probes suitable for hybridizing with at least 20 genes or gene fragments. On the basis of the hybridization results, the rheumatic condition is determined.

Abstract: The present invention relates to a nanowire array (15, 16) for electrically-controlled elution of a therapeutic composition (5) comprising a plurality of nanoscopic-sized wires (12, 12), nanowires, attached to an electrically conducting solid support (7), said nanowires formed from electroactive conjugated polymer (4) containing or doped with said therapeutic composition (5) coated over a plurality of nanoscopic sized electrically conducting protrusions (8). It also relates to a method for preparing a nanowire array and an electrode.

Abstract: Methods and hosts for rearing insect parasitoids are provided. Particularly, polymer beads (alginate, carrageenan, and chitosan) are used to rear endoparasitoids in vitro.

Abstract: An assay for detecting and identifying micro-organisms, particularly bacteria, is disclosed. In particular, an assay for detecting bacteria in a sample is disclosed. Bacteria are identified according to Gram-, genus- species- and strain-specificity based on multigenotypic testing of bacterial DNA from human, animal or environmental samples.

Abstract: A method, device and kit are disclosed for determining a condition related to dysfunction of the Renal Proximal Tubule (RPT) by detecting the presence of type III Carbonic Anhydrase, CAIII, in a urine sample of a subject. The method is used for diagnosis and to monitor the progress of a condition, and to determine the efficacy of a treatment.

Abstract: The present invention concerns hybrid manual-robotic system for supporting and moving a surgical instrument having active main structure (100) that comprises: a) a base (2) for attachment to an operating table having an operating surface (150); b) a hexahedral-shape frame (3), which shape is formed from a first (5, 5?) and second (4, 4?) pair of opposing parallelograms and opposing proximal (6?) and distal (6) rectangles, which frame (3) is formed by at least seven links (7, 8, 9, 10, 11, 12, 13, 22, 23) connected by revolute joints (14, 15, 16, 17, 18, 19, 20, 26, 27, 109), whereby a) a pair of parallel base links (7, 13) of the proximal rectangle (6?) is coupled to the base (2) by two revolute joints (116, 117), and are configured to lie and remain essentially perpendicular to the plane of the 10 operating surface (150) and to revolve around their longitudinal axes that coincide with the axes of revolution of joints (116, 117), whereby b) said revolute joints are configured to allow the hexahedral frame (3)

Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.

Abstract: The present invention relates to genes responsible for disorders with a vascular component, the identification of mutations in said genes and the detection of their sequences as well as methods for detection and treatment for disorders with a vascular component. This invention further relates to proteins encoded by said genes and their applications.

Abstract: The present invention relates to azo dyes, in particular azo dyes of Formula (I) or (II), a tautomer, a quaternary amine, or a salt thereof, wherein R1, R2a, R2b, R3, R4, R5, R3, R7, R8, R9, R10, R11 have the same meaning as in the claims. The present invention also relates to processes for preparing said compounds, compositions containing them and their use as dyes.

Abstract: The present invention relates to a method for the preparation of a compound of formula (I) or pharmaceutically acceptable salts thereof and intermediates thereof, comprising the steps of: a) halogenating a compound of formula (II), resulting in compound of formula (IIa), b) reacting a compound of formula (IIa) at its 14 position with the thiol moiety of a peptide of formula (III), optionally in the presence of a suitable linker, to obtain said compound of formula (I), wherein R1 represents OH, NH2 or NH-peptide; R2 represents H or —CO-peptide; R3 represents OCH3, OH or H; R4 represents H, or COCF3; R5 represents OH, O-tetrahydropyranyl or H; R6 represents OH or H; R7 represents H, OH, OCO(CH2)3CH3 or OCOCH(OC2H5)2; R8 represents OH or H; R9 represents OH or H; R10 represents a halogen and L is an optional suitable linker arm.

Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

Abstract: Compositions and a method for sensitizing a cancer for treatment by cytotoxic therapy is disclosed. The method includes the step of administering to the cancerous tissue or cells a pharmaceutical composition containing a Botulinum toxin, BT.